Medis Medical Imaging partners with CORRIB Core Lab and SINOMED, to study impact of Quantitative Flow Ratio (QFR®) on appropriateness of revascularization in the PIONEER-IV randomized clinical trial
This PIONEER IV study is a randomized, multicenter trial comparing clinical outcomes between angiography-derived physiology guidance by QFR® of Medis Medical Imaging and local routine diagnostic procedure and usual care in an all-comers patient population undergoing PCI with an unrestricted use of SINOMED’s new drug-eluting stent, the Healing-Targeted Supreme Stent (HT Supreme).
The PIONEER-IV study will involve careful physiological identification of heart blood vessels that need to be treated or deferred. A narrowing located in a coronary vessel is deemed flow limiting if QFR <0.80 . After stenting, the QFR measurement is repeated in the stented vessel(s) to verify the success of the intervention. In case distal QFR is <0.91 or delta QFR (across the stent is >0.05), post-dilatation of stented segment or additional stenting is recommended.
Read the full press release here
Learn more on the benefits of QFR®